Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ängeby K[au]:

Search results

Items: 36

1.

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.

Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, Ängeby K, Jureen P, Moradigaravand D, Parkhill J, Peacock SJ, Schön T, Maurer FP, Walker T, Köser C, Niemann S.

Genome Med. 2020 Mar 6;12(1):27. doi: 10.1186/s13073-020-00726-5.

2.

Women's labour experiences and quality of care in relation to a prolonged latent phase of labour.

Ängeby K, Sandin-Bojö AK, Persenius M, Wilde-Larsson B.

Midwifery. 2019 Oct;77:155-164. doi: 10.1016/j.midw.2019.07.006. Epub 2019 Jul 9.

PMID:
31369936
3.

Early labour experience questionnaire: Psychometric testing and women's experiences in a Swedish setting.

Ängeby K, Sandin-Bojö AK, Persenius M, Wilde-Larsson B.

Midwifery. 2018 Sep;64:77-84. doi: 10.1016/j.midw.2018.06.008. Epub 2018 Jun 22.

PMID:
29966880
4.

Prevalence of Prolonged Latent Phase and Labor Outcomes: Review of Birth Records in a Swedish Population.

Ängeby K, Wilde-Larsson B, Hildingsson I, Sandin-Bojö AK.

J Midwifery Womens Health. 2018 Jan;63(1):33-44. doi: 10.1111/jmwh.12704.

PMID:
29419927
5.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

6.

Primiparous women's preferences for care during a prolonged latent phase of labour.

Ängeby K, Wilde-Larsson B, Hildingsson I, Sandin-Bojö AK.

Sex Reprod Healthc. 2015 Oct;6(3):145-50. doi: 10.1016/j.srhc.2015.02.003. Epub 2015 Feb 24.

PMID:
26842637
7.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
8.

Otomastoiditis caused by non-tuberculous mycobacteria: report of 16 cases, 3 with infection intracranially.

Lundman L, Edvardsson H, Ängeby K.

J Laryngol Otol. 2015 Jul;129(7):644-55. doi: 10.1017/S0022215115001309.

PMID:
26153833
9.

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

10.

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T.

Clin Microbiol Infect. 2015 Feb;21(2):148.e5-7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29.

11.

Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Schön T, Simonsson US, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K.

Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22.

12.

A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability.

Larsson MC, Lerm M, Ängeby K, Nordvall M, Juréen P, Schön T.

J Microbiol Methods. 2014 Nov;106:146-150. doi: 10.1016/j.mimet.2014.08.015. Epub 2014 Sep 3.

PMID:
25194234
13.

A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting.

Wedajo W, Schön T, Bedru A, Kiros T, Hailu E, Mebrahtu T, Yamuah L, Ängeby K, Werngren J, Onyebujoh P, Dagne K, Aseffa A.

BMC Res Notes. 2014 Aug 10;7:512. doi: 10.1186/1756-0500-7-512.

14.

Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.

Hoffner S, Angeby K, Sturegård E, Jönsson B, Johansson A, Sellin M, Werngren J.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1486-90. doi: 10.5588/ijtld.13.0195.

PMID:
24125455
15.

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

Schön T, Juréen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Angeby K.

J Antimicrob Chemother. 2013 Sep;68(9):2074-7. doi: 10.1093/jac/dkt150. Epub 2013 Apr 30.

PMID:
23633684
16.

The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen PN, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gómez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Mannsåker T, Marras TK, Maugein J, Milburn HJ, Mlinkó T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Peña M, Piersimoni C, Polanová M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabó N, Thomson R, Tórtola Fernandez T, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D; Nontuberculous Mycobacteria Network European Trials Group.

Eur Respir J. 2013 Dec;42(6):1604-13. doi: 10.1183/09031936.00149212. Epub 2013 Apr 18.

17.

Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.

Ängeby K, Juréen P, Chryssanthou E, Schön T.

Int J Mycobacteriol. 2012 Dec;1(4):177-9. doi: 10.1016/j.ijmyco.2012.09.002. Epub 2012 Oct 11.

18.

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T.

Bull World Health Organ. 2012 Sep 1;90(9):693-8. doi: 10.2471/BLT.11.096644. Epub 2012 May 29.

19.

Resistance to first-line anti-TB drugs is associated with reduced nitric oxide susceptibility in Mycobacterium tuberculosis.

Idh J, Mekonnen M, Abate E, Wedajo W, Werngren J, Ängeby K, Lerm M, Elias D, Sundqvist T, Aseffa A, Stendahl O, Schön T.

PLoS One. 2012;7(6):e39891. doi: 10.1371/journal.pone.0039891. Epub 2012 Jun 29.

20.

The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden.

Chryssanthou E, Angeby K.

APMIS. 2012 May;120(5):405-9. doi: 10.1111/j.1600-0463.2011.02845.x. Epub 2011 Nov 28.

PMID:
22515295
21.

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1253-7. doi: 10.1128/AAC.05894-11. Epub 2011 Dec 27.

22.

Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.

Angeby K, Giske CG, Juréen P, Schön T, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2011 Sep;55(9):4492-3; author reply 4493. doi: 10.1128/AAC.00232-11. No abstract available.

23.

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

Schön T, Juréen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G, Hoffner S, Angeby KA.

Int J Tuberc Lung Dis. 2011 Apr;15(4):502-9. doi: 10.5588/ijtld.10.0238.

PMID:
21396210
24.

Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Grönberg A, Zettergren L, Bergh K, Ståhle M, Heilborn J, Angeby K, Small PL, Akuffo H, Britton S.

PLoS One. 2010 Nov 4;5(11):e13839. doi: 10.1371/journal.pone.0013839.

25.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23.

PMID:
20332195
26.

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T.

J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17.

27.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.

PMID:
19633001
28.

The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.

Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K.

J Antimicrob Chemother. 2008 Jul;62(1):56-64. doi: 10.1093/jac/dkn139. Epub 2008 Apr 10. Review.

PMID:
18407918
29.
30.
31.

Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis.

Angeby KA, Werngren J, Toro JC, Hedström G, Petrini B, Hoffner SE.

Clin Microbiol Infect. 2003 Nov;9(11):1148-52.

32.
33.

Improved sputum microscopy for a more sensitive diagnosis of pulmonary tuberculosis.

Angeby KA, Alvarado-Gálvez C, Pineda-García L, Hoffner SE.

Int J Tuberc Lung Dis. 2000 Jul;4(7):684-7.

PMID:
10907772
35.

Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.

Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L.

Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74.

PMID:
6149133
36.

The 'presynaptic' blocking potency of sulpiride and haloperidol in the rat is age-dependent.

Ogren SO, Rodebjer A, Angeby K.

Neurosci Lett. 1984 May 4;46(2):203-7.

PMID:
6738914

Supplemental Content

Loading ...
Support Center